Nuclera, a biotech company developing enzymatic protein and gene synthesis technologies, and E Ink, the innovator of electronic ink technology, have announced the acquisition of E Ink’s digital microfluidics unit into the newly formed US subsidiary of Nuclera.
The company said in a statement, “Combining the technologies of the two companies will enable the delivery of a revolutionary desktop protein and gene “bioprinter” with breakthrough speed and convenience for researchers in human health, agriculture, and other markets of global importance.”
“In the transaction, E Ink will contribute intellectual property, equipment, and highly specialized scientists and engineers. Reciprocally, E Ink will become the largest strategic shareholder in Nuclera. The resulting Nuclera US subsidiary will be co-located within the E Ink Innovation Center in Billerica, MA, a short distance from the growing biotech technology hub in Cambridge, MA. The combination of these two efforts into one company will further increase the rate of development, commercialization, and adoption of this ground-breaking product as well as consolidate the intellectual property position. E Ink will continue to be a strategic supplier to Nuclera for key electronic components of Nuclera’s desktop bioprinter,” the statement added.
Arya has been a part of the Content & Research Team at Hrnxt.com. She is a keen observer of economic developments, emerging businesses, people in business and keeps a tab on latest happenings in the business environment.